Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant

Contrave, A New Weight Loss Pill Combines Anti-Addiction Medication And An Antidepressant.


An maven consultative panel recommended on Tuesday that Contrave, a changed weight-loss medication that combines an antidepressant with an anti-addiction medication, be approved by the US Food and Drug Administration. The 13-7 elector in favor of Contrave came mid means concerns that the dose might present blood pressure in some patients and swell the risk of heart attacks and strokes middle some users, according to the Associated Press education science locking and arresting mechanisms . But panelists voted 11-8 earlier in the hour that those concealed health risks could be studied after Contrave was approved.



The FDA does not have to follow the guidance of its advisory committees, but it typically does. The mechanism is expected to suppose a decision on Contrave by Jan 31, 2011, the wire worship reported. contrave is manufactured by orexigen therapeutics inc. In October, the FDA voted against approving two other weight-loss drugs, Arena Pharmaceuticals' lorcaserin and Vivus' Qnexa, because of protection concerns, according to the AP herbal enhancements for the breast. Last July, a over funded by Orexigen and published in The Lancet found that Contrave helped users cast pounds when enchanted along with a well assembly and exercise.



People who took the poison for more than a year puzzled an ordinary of 5 percent or more of body weight, depending on the portion used, the team said. However, the regimen did come with part effects, and about half of memorize participants dropped out before completing a year of treatment. Contrave is association of two celebrated drugs, naltrexone (Revia, used to strive addictions) and the antidepressant bupropion (known by a sum of names, including Wellbutrin).



The drug appears to aid weight loss by changing the workings of the body's significant nervous system, the researchers said. The inspect enrolled men (15 percent) and women (85 percent) from around the country, ranging in lifetime from 18 to 65. They were all either corpulent or overweightm, with exalted blood paunchy levels or high blood pressure.